文献速递垂体与肾上腺疾病性腺与生殖内分泌

口服避孕药与绝经期激素治疗使用及垂体腺瘤风险:队列与病例对照分析

Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

95%CI,1.50-2.68)和当前使用(MVHR=1.80;95%CI,1.27-2.55)与垂体腺瘤风险相关,使用超过5年风险更高(MVHR=2.06;95%CI,1.42-2.99;P趋势=.002);口服避孕药(OC)使用与风险无关。在病例对照分析(5469例病例)中,MHT(MVOR=1.57;95%CI,1.35-1.83)和OC(MVOR=1.27;95%CI,1.14-1.42)曾使用均与风险升高相关。

要点

  • 队列分析中,MHT过去使用和当前使用与垂体腺瘤风险正相关,使用超过5年风险更高。
  • 队列分析中,OC过去使用和当前使用与垂体腺瘤风险无关。
  • 病例对照分析中,MHT和OC曾使用均与垂体腺瘤风险轻度升高相关。

核心结论

  • 与从未使用相比,当前和过去MHT使用及更长MHT使用时长在两个独立数据集中与垂体腺瘤风险升高正相关。
  • OC使用在前瞻性队列分析中与风险无关,在病例对照分析中仅与轻度风险升高相关。

研究设计与样本

  • 在护士健康研究(Nurses' Health Study)和护士健康研究II(Nurses' Health Study II)中,使用Cox比例风险模型计算OC/MHT使用与垂体腺瘤风险的多变量校正风险比(MVHR)。
  • 同时利用机构数据仓库开展匹配病例对照研究,计算OC/MHT使用与垂体腺瘤风险的多变量校正比值比(MVOR)。

主要发现

  • 队列分析随访6 668 019人年,331名参与者报告垂体腺瘤诊断。
  • 与从未使用OC者相比,过去使用OC的MVHR=1.05(95%CI,0.80-1.36),当前使用OC的MVHR=0.72(95%CI,0.40-1.32)。
  • 与从未使用MHT者相比,过去使用MHT的MVHR=2.00(95%CI,1.50-2.68),当前使用MHT的MVHR=1.80(95%CI,1.27-2.55)。
  • 与从未使用MHT者相比,使用超过5年的MVHR=2.06(95%CI,1.42-2.99),P趋势=.002。
  • 病例对照分析纳入5469例病例,与从未使用者相比,曾使用MHT的MVOR=1.57(95%CI,1.35-1.83),曾使用OC的MVOR=1.27(95%CI,1.14-1.42)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: No prospective epidemiologic studies have examined associations between use of oral contraceptives (OCs) or menopausal hormone therapy (MHT) and risk of pituitary adenoma in women. OBJECTIVE: Our aim was to determine the association between use of OC and MHT and risk of pituitary adenoma in two separate datasets. METHODS: We evaluated the association of OC/MHT with risk of pituitary adenoma in the Nurses' Health Study and Nurses' Health Study II by computing multivariable-adjusted hazard ratios (MVHR) of pituitary adenoma by OC/MHT use using Cox proportional hazards models. Simultaneously, we carried out a matched case-control study using an institutional data repository to compute multivariable-adjusted odds ratios (MVOR) of pituitary adenoma by OC/MHT use. RESULTS: In the cohort analysis, during 6 668 019 person-years, 331 participants reported a diagnosis of pituitary adenoma. Compared to never-users, neither past (MVHR = 1.05; 95% CI, 0.80-1.36) nor current OC use (MVHR = 0.72; 95% CI, 0.40-1.32) was associated with risk. For MHT, compared to never-users, both past (MVHR = 2.00; 95% CI, 1.50-2.68) and current use (MVHR = 1.80; 95% CI, 1.27-2.55) were associated with pituitary adenoma risk, as was longer duration (MVHR = 2.06; 95% CI, 1.42-2.99 comparing more than 5 years of use to never, P trend = .002). Results were similar in lagged analyses, when stratified by body mass index, and among those with recent health care use. In the case-control analysis, we included 5469 cases. Risk of pituitary adenoma was increased with ever use of MHT (MVOR = 1.57; 95% CI, 1.35-1.83) and OC (MVOR = 1.27; 95% CI, 1.14-1.42) compared to never. CONCLUSION: Compared to never use, current and past MHT use and longer duration of MHT use were positively associated with higher risk of pituitary adenoma in 2 independent data sets. OC use was not associated with risk in the prospective cohort analysis and was associated with only mildly increased risk in the case-control analysis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cote DJ, Kilgallon JL, Nawabi NLA, et al. Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses. J Clin Endocrinol Metab. 2022. PMID: 34865056. doi:10.1210/clinem/dgab868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。